Inozyme Pharma Inc at Bank of America Healthcare Conference Transcript
Thanks for joining us. My name is Leon Wang, Tazeen Ahmad's associate, and it is my pleasure to introduce Axel, CEO of Inozyme. Axel, take it away.
Thank you very much. Great to be here. Great to have an in-person conference again. So five years ago, Inozyme was founded because of an unmet therapeutic need in devastating human diseases caused by abnormal absorption of minerals in the body. And what was then a promising scientific opportunity today is a new paradigm in the treatment of these disorders.
I'd like to point you to our forward-looking statements. So Inozyme is leading the development of therapeutic options where there are currently none. Our clinical program is well underway in our two lead indications: ENPP1 deficiency and ABCC6 deficiency. And our enzyme replacement therapy, INZ-701, has shown promising results in the first cohort of our ongoing ENPP1-deficient -- trial in ENPP1-deficient patients. And in the next few months, we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
